期刊文献+

Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations 被引量:6

Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations
下载PDF
导出
摘要 AIM: To investigate the genotype and allelic frequencies of Cytochrome P450 2B6 polymorphisms in four southern Chinese populations.METHODS: DNA was obtained from blood samples from Han Chinese from Hong Kong and three minority groups,the Wa, Bulang and Lahu from Yunnan in southern China. Genotyping was performed using real-time PCR and confirmed by direct sequencing.RESULTS: A total of 507 subjects from southern China were studied. Results showed there is a high prevalence of 516G 〉 T (34.5%) in ethnic Chinese compared to literature reports on other Asian populations and Caucasians. The frequency of the 516TT genotype is higher in the Hah majority (23.1%) than in three other ethnic minority groups (i.e., 7.4%, 9.1% and 15.8%) in southern China.CONCLUSION: This was the first study to document the spectrum of CYP2B6 allelic variants and genotypes in a southern Chinese population. The 516G 〉 T allele is associated with a defective metabolism of efavirenz (EFV), which therefore may predispose to drug toxicity.Treatment regimens for human immunodeficiency virus (HIV) and heroin addiction may need to be optimized in different populations because of the marked variability of the key metabolizing enzyme. 瞄准:在四张南部的中国人口调查遗传型和细胞色素 P450 2B6 多型性的突变而产生之遗传的频率。方法:DNA 从香港和三个少数从汉汉语从血样品被获得从在南部的中国的云南的组, Wa, Bulang 和拉枯族。Genotyping 用即时 PCR 被执行并且由直接定序证实了。结果:从南部的中国的 507 个题目的一个总数被学习。结果证明用与另外的亚洲人口和白种人上的文学报告相比的种族汉语有 516G > T (34.5%) 的高流行。516TT 遗传型的频率比在三个另外的种族少数组在汉多数(23.1%) 是更高的(即, 7.4% , 9.1% 和 15.8%) 在南部的中国。结论:这是第一研究在一张南部的中国人口记录 CYP2B6 突变而产生之遗传的变体和遗传型的光谱。516G > T 等位基因与 efavirenz (EFV ) 的有缺点的新陈代谢被联系,它可以因此预先安排到药毒性。因为关键使人的免疫不全病毒(HIV ) 和海洛因嗜好产生代射变化酶的显著可变性,为的处理政体可以需要在不同人口被优化。
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第14期2100-2103,共4页 世界胃肠病学杂志(英文版)
基金 Supported by The South China National Research Centre for Integrated Biosciences, and has been conducted collaboratively between Zhongshan University (ZU) The Chinese University of Hong Kong
关键词 Polymorphism ALLELE GENOTYPE ETHNICITY Discrimination PCR CYP2B6多态性 中国人 华南人群 遗传变异性
  • 相关文献

参考文献16

  • 1[1]Pascussi JM,Gerbal-Chaloin S,Drocourt L,Maurel P,Vilarem MJ.The expression of CYP2B6,CYP2C9 and CYP3A4 genes:a tangle of networks of nuclear and steroid receptors.Biochim Biophys Acta 2003; 1619:243-253
  • 2[2]Lang T,Klein K,Fischer J,Nussler AK,Neuhaus P,Hofmann U,Eichelbaum M,Schwab M,Zanger UM.Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.Pharmacogenetics 2001;11:399-415
  • 3[3]Haas DW,Ribaudo HJ,Kim RB,Tierney C,Wilkinson GR,Gulick RM,Clifford DB,Hulgan T,Marzolini C,Acosta EP.Pharmacogenetics of efavirenz and central nervous system side effects:an Adult AIDS Clinical Trials Group study.AIDS 2004; 18:2391-2400
  • 4[4]Tsuchiya K,Gatanaga H,Tachikawa N,Teruya K,Kikuchi Y,Yoshino M,Kuwahara T,Shirasaka T,Kimura S,Oka S.Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.Biochem Biophys Res Commun 2004; 319:1322-1326
  • 5[5]Zukunft J,Lang T,Richter T,Hirsch-Ernst KI,Nussler AK,Klein K,Schwab M,Eichelbaum M,Zanger UM.A naturalCYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.Mol Pharmacol 2005; 67:1772-1782
  • 6[6]Kirchheiner J,Klein C,Meineke I,Sasse J,Zanger UM,Murdter TE,Roots I,Brockmoller J.Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.Pharmacogenetics 2003; 13:619-626
  • 7[7]Lamba V,Lamba J,Yasuda K,Strom S,Davila J,Hancock ML,Fackenthal JD,Rogan PK,Ring B,Wrighton SA,Schuetz EG.Hepatic CYP2B6 expression:gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.J Pharmacol Exp Ther 2003;307:906-922
  • 8[8]Crettol S,Deglon JJ,Besson J,Croquette-Krokkar M,Gothuey I,Hammig R,Monnat M,Huttemann H,Baumann P,Eap CB.Methadone enantiomer plasma levels,CYP2B6,CYP2C19,and CYP2C9 genotypes,and response to treatment.Clin Pharmacol Ther 2005; 78:593-604
  • 9[9]Haas DW,Smeaton LM,Shafer RW,Robbins GK,Morse GD,Labbe L,Wilkinson GR,Clifford DB,D'Aquila RT,De Gruttola V,Pollard RB,Merigan TC,Hirsch MS,George AL Jr,Donahue JP,Kim RB.Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir:an Adult Aids Clinical Trials Group Study.J Infect Dis 2005; 192:1931-1942
  • 10[10]Jacob RM,Johnstone EC,Neville MJ,Walton RT.Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping.Clin Chem 2004; 50:1372-1377

同被引文献17

  • 1Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human tire[ J ]. Pharmacogenetics, 2001,11: 399 - 415.
  • 2Hass DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and nervous system side effects: an Adult AIDS Clinical trials Group study[J]. aids, 2004,18:2391 - 2400.
  • 3Tsuchiya K, Gatanaga H, Tachikawa N, Homozygous CYP2B6*6 (Q172H and K262R)correlas with high plasma efavirenz concentration inHIV-1 patients treated with standard efavirenze-containing regimens[J].Biochem Biophys Res Commun, 2004,19:1322- 1326.
  • 4Rodriguez- Novoa Sonia, BARREIRO Pablo, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects[J]. Clinical infectious diseases, 2005,40 (9) : 1358 - 1361.
  • 5Osamu Usami, Yuao Ashino, et al. Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 * 2/*2(C64T)[J] .Int J STD AIDS,2007,18:575 - 576.
  • 6Dirk Theile,Walter Emil Haefeli,Helmut Karl Seitz,Gunda Millonig,Johanna Weiss,Sebastian Mueller.Association of Liver Stiffness with Hepatic Expression of Pharmacokinetically Important Genes in Alcoholic Liver Disease[J].Alcohol Clin Exp Res.2012
  • 7Albader Albarmawi,David Czock,Annika Gauss,Robert Ehehalt,Justo Lorenzo Bermejo,Jürgen Burhenne,Tom M. Ganten,Peter Sauer,Walter E. Haefeli.CYP3A activity in severe liver cirrhosis correlates with C hild– P ugh and model for end‐stage liver disease ( MELD ) scores[J].Br J Clin Pharmacol.2014(1)
  • 8Ioannis Koutsounas,Stamatios Theocharis,Efstratios Patsouris,Constantinos Giaginis.Pregnane X Receptor (PXR) at the Crossroads of Human Metabolism and Disease[J].Current Drug Metabolism.2013(3)
  • 9Iain A.M. MacPhee.Pharmacogenetic biomarkers: cytochrome P450 3A5[J].Clinica Chimica Acta (-).2011(17-18)
  • 10J. Aubert,K. Begriche,L. Knockaert,M.A. Robin,B. Fromenty.Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role[J].Clinics and Research in Hepatology and Gastroenterology.2011(10)

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部